支气管扩展剂反应:在接受造血干细胞移植的患者中的有用性和影响
Reid H Eggleston1, Mehrdad Hefazi Torghabeh2, Alexander S Niven1
1Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Respiratory medicine
|July 17, 2025
概括
在血液细胞移植 (HCT) 之前进行支气管扩展剂反应测试,对于支气管炎消灭综合征 (BOS) 或生存等结果的预后价值很小. 这表明在HCT协议中消除常规BDR评估可能是可行的.
科学领域:
- 肺部医学 肺部医学
- 造血细胞移植 造血细胞移植
- 呼吸系统生理学 呼吸系统生理学
背景情况:
- 支气管扩展剂反应 (BDR) 评估是血造细胞移植前 (HCT) 肺评价的标准.
- 在HCT接受者中,BDR的预后意义是不确定的,特别是随着欧洲呼吸学会/美国胸腔学会 (ERS/ATS) 标准的不断变化.
- 了解BDR的作用对于准确评估HCT候选者的风险至关重要.
研究的目的:
- 调查移植前BDR与异构HCT接受者的临床结果之间的关联.
- 为了比较传统的 (2005年) 与修订的 (2022年) BDR标准的预后效用.
- 为了确定BDR是否预测了支气管炎消灭综合征 (BOS) 的发展.
主要方法:
- 一项单一中心研究包括1,255名成年异构HCT接受者 (2005-2021年).
- 用2005年 (FEV1/FVC增加≥12%和≥200毫升) 和2022年 (预测增加的≥10%) 两个标准来评估BDR.
- 分析的主要结局是BOS发育,120天的ICU入院和生存.
主要成果:
- 阳性BDR率很低 (2005年标准为11.5%,2022年标准为14.2%),一致性很高.
- 移植前的BDR没有预测BOS的发展;FEV1反应在患有和没有患有BOS的患者中是相似的.
- 未调整的BDR阳性与更高的死亡率和ICU入院有关,但在调整基线FEV1.1后,这些关联消失了.
结论:
- 支气管扩展剂反应测试在HCT接受者中提供了基线肺功能之外的最小预后信息.
- BDR测试不能预测BOS的发展,表明BOS是一个独特的纤维增殖过程.
- 在不影响风险评估的情况下,可以考虑从HCT协议中取消常规BDR测试.
相关概念视频
Bone Marrow Sampling and Transplants
502
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
502
COPD: Management Using Bronchodilators and Corticosteroids
319
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
319
Drugs Used in Lower Respiratory Disorders: Overview
599
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
599
Antiasthma Drugs: β2-Adrenoceptor Agonists
392
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
392


